APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Therapy for Cancer

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti-VEGF Therapy for Cancer Market Analysis and Forecast 2026-2032

27 December 2025197 pages

Choose your research edition.

Industry ResearchAnti-VEGF Therapy for Cancer Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Therapy for Cancer Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Therapy for Cancer Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Therapy for Cancer Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Therapy for Cancer Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-VEGF Therapy for Cancer market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti-VEGF Therapy for Cancer is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Anti-VEGF Therapy for Cancer include Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Sanofi, Roche, Pfizer, Novartis, Janssen Biotech, Exelixis and Eli Lilly, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Anti-VEGF Therapy for Cancer, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti-VEGF Therapy for Cancer, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti-VEGF Therapy for Cancer, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti-VEGF Therapy for Cancer revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti-VEGF Therapy for Cancer market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti-VEGF Therapy for Cancer revenue, projected growth trends, production technology, application and end-user industry.

Anti-VEGF Therapy for Cancer Segment by Company

Chia Tai Tianqing

Jiangsu Hengrui Pharmaceuticals

Sanofi

Roche

Pfizer

Novartis

Janssen Biotech

Exelixis

Eli Lilly

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca

Anti-VEGF Therapy for Cancer Segment by Type

VEGF Inhibitors

VEGFR Inhibitors

Anti-VEGF Therapy for Cancer Segment by Application

Non-small Cell Lung Cancer

Cervical Cancer

Colorectal Cancer

Renal Cell Carcinoma

Medullary Thyroid Cancer

Other

Anti-VEGF Therapy for Cancer Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Therapy for Cancer market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Therapy for Cancer and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Therapy for Cancer.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anti-VEGF Therapy for Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anti-VEGF Therapy for Cancer company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti-VEGF Therapy for Cancer revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. VEGF Inhibitors Major Player Table 3. VEGFR Inhibitors Major Player Table 4. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Non-small Cell Lung Cancer Major Player Table 6. Cervical Cancer Major Player Table 7. Colorectal Cancer Major Player Table 8. Renal Cell Carcinoma Major Player Table 9. Medullary Thyroid Cancer Major Player Table 10. Other Major Player Table 11. Anti-VEGF Therapy for Cancer Industry Trends Table 12. Anti-VEGF Therapy for Cancer Industry Drivers Table 13. Anti-VEGF Therapy for Cancer Industry Opportunities and Challenges Table 14. Anti-VEGF Therapy for Cancer Industry Restraints Table 15. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Anti-VEGF Therapy for Cancer Market Share by Region (2021-2026) Table 18. Global Anti-VEGF Therapy for Cancer Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Anti-VEGF Therapy for Cancer Market Share by Region (2027-2032) Table 20. Global Anti-VEGF Therapy for Cancer Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Players (2021-2026) Table 22. Global Anti-VEGF Therapy for Cancer Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Anti-VEGF Therapy for Cancer Key Players Headquarters & Area Served Table 24. Global Anti-VEGF Therapy for Cancer Players, Product Type & Application Table 25. Global Anti-VEGF Therapy for Cancer Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Anti-VEGF Therapy for Cancer by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Anti-VEGF Therapy for Cancer Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2021-2026) Table 32. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2027-2032) Table 33. Global Anti-VEGF Therapy for Cancer Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2021-2026) Table 37. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2027-2032) Table 38. Chia Tai Tianqing Company Information Table 39. Chia Tai Tianqing Business Overview Table 40. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio Table 42. Chia Tai Tianqing Recent Development Table 43. Jiangsu Hengrui Pharmaceuticals Company Information Table 44. Jiangsu Hengrui Pharmaceuticals Business Overview Table 45. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio Table 47. Jiangsu Hengrui Pharmaceuticals Recent Development Table 48. Sanofi Company Information Table 49. Sanofi Business Overview Table 50. Sanofi Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Sanofi Anti-VEGF Therapy for Cancer Product Portfolio Table 52. Sanofi Recent Development Table 53. Roche Company Information Table 54. Roche Business Overview Table 55. Roche Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Roche Anti-VEGF Therapy for Cancer Product Portfolio Table 57. Roche Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Pfizer Anti-VEGF Therapy for Cancer Product Portfolio Table 62. Pfizer Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Novartis Anti-VEGF Therapy for Cancer Product Portfolio Table 67. Novartis Recent Development Table 68. Janssen Biotech Company Information Table 69. Janssen Biotech Business Overview Table 70. Janssen Biotech Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio Table 72. Janssen Biotech Recent Development Table 73. Exelixis Company Information Table 74. Exelixis Business Overview Table 75. Exelixis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Exelixis Anti-VEGF Therapy for Cancer Product Portfolio Table 77. Exelixis Recent Development Table 78. Eli Lilly Company Information Table 79. Eli Lilly Business Overview Table 80. Eli Lilly Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio Table 82. Eli Lilly Recent Development Table 83. Eisai Company Information Table 84. Eisai Business Overview Table 85. Eisai Anti-VEGF Therapy for Cancer Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Eisai Anti-VEGF Therapy for Cancer Product Portfolio Table 87. Eisai Recent Development Table 88. Boehringer Ingelheim Company Information Table 89. Boehringer Ingelheim Business Overview Table 90. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio Table 92. Boehringer Ingelheim Recent Development Table 93. Bayer Company Information Table 94. Bayer Business Overview Table 95. Bayer Anti-VEGF Therapy for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Bayer Anti-VEGF Therapy for Cancer Product Portfolio Table 97. Bayer Recent Development Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Anti-VEGF Therapy for Cancer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio Table 102. AstraZeneca Recent Development Table 103. North America Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 104. North America Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 105. North America Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 106. North America Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 107. North America Anti-VEGF Therapy for Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. North America Anti-VEGF Therapy for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 109. North America Anti-VEGF Therapy for Cancer Revenue by Country (US$ Million) & (2027-2032) Table 110. Europe Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 111. Europe Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 112. Europe Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 113. Europe Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 114. Europe Anti-VEGF Therapy for Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Europe Anti-VEGF Therapy for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Anti-VEGF Therapy for Cancer Revenue by Country (US$ Million) & (2027-2032) Table 117. China Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 118. China Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 119. China Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 120. China Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 121. Asia Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 122. Asia Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 123. Asia Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 124. Asia Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia Anti-VEGF Therapy for Cancer Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 126. Asia Anti-VEGF Therapy for Cancer Revenue by Region (US$ Million) & (2021-2026) Table 127. Asia Anti-VEGF Therapy for Cancer Revenue by Region (US$ Million) & (2027-2032) Table 128. SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026) & (US$ Million) Table 129. SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032) & (US$ Million) Table 130. SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026) & (US$ Million) Table 131. SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032) & (US$ Million) Table 132. SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2021-2026) & (US$ Million) Table 134. SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (US$ Million) & (2027-2032) Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Anti-VEGF Therapy for Cancer Image Figure 2. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Therapy for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 4. VEGF Inhibitors Image Figure 5. VEGFR Inhibitors Image Figure 6. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti-VEGF Therapy for Cancer Market Size Share 2021 VS 2025 VS 2032 Figure 8. Non-small Cell Lung Cancer Image Figure 9. Cervical Cancer Image Figure 10. Colorectal Cancer Image Figure 11. Renal Cell Carcinoma Image Figure 12. Medullary Thyroid Cancer Image Figure 13. Other Image Figure 14. Global Anti-VEGF Therapy for Cancer Market Size (US$ Million) & (2021-2032) Figure 15. Global Anti-VEGF Therapy for Cancer Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Anti-VEGF Therapy for Cancer Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Anti-VEGF Therapy for Cancer Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Anti-VEGF Therapy for Cancer Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Anti-VEGF Therapy for Cancer Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2021-2032) Figure 22. Global Anti-VEGF Therapy for Cancer Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2021-2032) Figure 25. North America Anti-VEGF Therapy for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032) Figure 27. North America Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032) Figure 28. North America Anti-VEGF Therapy for Cancer Revenue Share by Country (2021-2032) Figure 29. United States Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Anti-VEGF Therapy for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032) Figure 34. Europe Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032) Figure 35. Europe Anti-VEGF Therapy for Cancer Revenue Share by Country (2021-2032) Figure 36. Germany Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Anti-VEGF Therapy for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032) Figure 46. China Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032) Figure 47. Asia Anti-VEGF Therapy for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032) Figure 49. Asia Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032) Figure 50. Asia Anti-VEGF Therapy for Cancer Revenue Share by Region (2021-2032) Figure 51. Japan Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Anti-VEGF Therapy for Cancer Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032) Figure 59. SAMEA Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032) Figure 60. SAMEA Anti-VEGF Therapy for Cancer Revenue Share by Country (2021-2032) Figure 61. Brazil Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Anti-VEGF Therapy for Cancer Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • VEGF Inhibitors
  • VEGFR Inhibitors
Applications
  • Non-small Cell Lung Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Renal Cell Carcinoma
  • Medullary Thyroid Cancer
  • Other
Companies covered
  • Chia Tai Tianqing
  • Jiangsu Hengrui Pharmaceuticals
  • Sanofi
  • Roche
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eli Lilly
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti-VEGF Therapy for Cancer Market by Type
  3. 1.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 VEGF Inhibitors
  5. 1.2.3 VEGFR Inhibitors
  6. 1.3 Anti-VEGF Therapy for Cancer Market by Application
  7. 1.3.1 Global Anti-VEGF Therapy for Cancer Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Non-small Cell Lung Cancer
  9. 1.3.3 Cervical Cancer
  10. 1.3.4 Colorectal Cancer
  11. 1.3.5 Renal Cell Carcinoma
  12. 1.3.6 Medullary Thyroid Cancer
  13. 1.3.7 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Anti-VEGF Therapy for Cancer Market Dynamics
  1. 2.1 Anti-VEGF Therapy for Cancer Industry Trends
  2. 2.2 Anti-VEGF Therapy for Cancer Industry Drivers
  3. 2.3 Anti-VEGF Therapy for Cancer Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Therapy for Cancer Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anti-VEGF Therapy for Cancer Market Perspective (2021-2032)
  2. 3.2 Global Anti-VEGF Therapy for Cancer Growth Trends by Region
  3. 3.2.1 Global Anti-VEGF Therapy for Cancer Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026)
  5. 3.2.3 Global Anti-VEGF Therapy for Cancer Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anti-VEGF Therapy for Cancer Revenue by Players
  2. 4.1.1 Global Anti-VEGF Therapy for Cancer Revenue by Players (2021-2026)
  3. 4.1.2 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anti-VEGF Therapy for Cancer Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti-VEGF Therapy for Cancer Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anti-VEGF Therapy for Cancer Key Players Headquarters & Area Served
  7. 4.4 Global Anti-VEGF Therapy for Cancer Players, Product Type & Application
  8. 4.5 Global Anti-VEGF Therapy for Cancer Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anti-VEGF Therapy for Cancer Market CR5 and HHI
  11. 4.6.3 2025 Anti-VEGF Therapy for Cancer Tier 1, Tier 2, and Tier 3
5 Anti-VEGF Therapy for Cancer Market Size by Type
  1. 5.1 Global Anti-VEGF Therapy for Cancer Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anti-VEGF Therapy for Cancer Revenue by Type (2021-2032)
  3. 5.3 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Type (2021-2032)
6 Anti-VEGF Therapy for Cancer Market Size by Application
  1. 6.1 Global Anti-VEGF Therapy for Cancer Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anti-VEGF Therapy for Cancer Revenue by Application (2021-2032)
  3. 6.3 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Chia Tai Tianqing
  2. 7.1.1 Chia Tai Tianqing Company Information
  3. 7.1.2 Chia Tai Tianqing Business Overview
  4. 7.1.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Portfolio
  6. 7.1.5 Chia Tai Tianqing Recent Developments
  7. 7.2 Jiangsu Hengrui Pharmaceuticals
  8. 7.2.1 Jiangsu Hengrui Pharmaceuticals Company Information
  9. 7.2.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  10. 7.2.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Portfolio
  12. 7.2.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Anti-VEGF Therapy for Cancer Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Roche
  20. 7.4.1 Roche Company Information
  21. 7.4.2 Roche Business Overview
  22. 7.4.3 Roche Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Roche Anti-VEGF Therapy for Cancer Product Portfolio
  24. 7.4.5 Roche Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Anti-VEGF Therapy for Cancer Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Novartis
  32. 7.6.1 Novartis Company Information
  33. 7.6.2 Novartis Business Overview
  34. 7.6.3 Novartis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novartis Anti-VEGF Therapy for Cancer Product Portfolio
  36. 7.6.5 Novartis Recent Developments
  37. 7.7 Janssen Biotech
  38. 7.7.1 Janssen Biotech Company Information
  39. 7.7.2 Janssen Biotech Business Overview
  40. 7.7.3 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Janssen Biotech Anti-VEGF Therapy for Cancer Product Portfolio
  42. 7.7.5 Janssen Biotech Recent Developments
  43. 7.8 Exelixis
  44. 7.8.1 Exelixis Company Information
  45. 7.8.2 Exelixis Business Overview
  46. 7.8.3 Exelixis Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Exelixis Anti-VEGF Therapy for Cancer Product Portfolio
  48. 7.8.5 Exelixis Recent Developments
  49. 7.9 Eli Lilly
  50. 7.9.1 Eli Lilly Company Information
  51. 7.9.2 Eli Lilly Business Overview
  52. 7.9.3 Eli Lilly Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Eli Lilly Anti-VEGF Therapy for Cancer Product Portfolio
  54. 7.9.5 Eli Lilly Recent Developments
  55. 7.10 Eisai
  56. 7.10.1 Eisai Company Information
  57. 7.10.2 Eisai Business Overview
  58. 7.10.3 Eisai Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eisai Anti-VEGF Therapy for Cancer Product Portfolio
  60. 7.10.5 Eisai Recent Developments
  61. 7.11 Boehringer Ingelheim
  62. 7.11.1 Boehringer Ingelheim Company Information
  63. 7.11.2 Boehringer Ingelheim Business Overview
  64. 7.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Portfolio
  66. 7.11.5 Boehringer Ingelheim Recent Developments
  67. 7.12 Bayer
  68. 7.12.1 Bayer Company Information
  69. 7.12.2 Bayer Business Overview
  70. 7.12.3 Bayer Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Bayer Anti-VEGF Therapy for Cancer Product Portfolio
  72. 7.12.5 Bayer Recent Developments
  73. 7.13 AstraZeneca
  74. 7.13.1 AstraZeneca Company Information
  75. 7.13.2 AstraZeneca Business Overview
  76. 7.13.3 AstraZeneca Anti-VEGF Therapy for Cancer Revenue and Gross Margin (2021-2026)
  77. 7.13.4 AstraZeneca Anti-VEGF Therapy for Cancer Product Portfolio
  78. 7.13.5 AstraZeneca Recent Developments
8 North America
  1. 8.1 North America Anti-VEGF Therapy for Cancer Revenue (2021-2032)
  2. 8.2 North America Anti-VEGF Therapy for Cancer Revenue by Type (2021-2032)
  3. 8.2.1 North America Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026)
  4. 8.2.2 North America Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032)
  5. 8.3 North America Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032)
  6. 8.4 North America Anti-VEGF Therapy for Cancer Revenue by Application (2021-2032)
  7. 8.4.1 North America Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026)
  8. 8.4.2 North America Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032)
  9. 8.5 North America Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032)
  10. 8.6 North America Anti-VEGF Therapy for Cancer Revenue by Country
  11. 8.6.1 North America Anti-VEGF Therapy for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anti-VEGF Therapy for Cancer Revenue by Country (2021-2026)
  13. 8.6.3 North America Anti-VEGF Therapy for Cancer Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Anti-VEGF Therapy for Cancer Revenue (2021-2032)
  2. 9.2 Europe Anti-VEGF Therapy for Cancer Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032)
  5. 9.3 Europe Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anti-VEGF Therapy for Cancer Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032)
  9. 9.5 Europe Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anti-VEGF Therapy for Cancer Revenue by Country
  11. 9.6.1 Europe Anti-VEGF Therapy for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anti-VEGF Therapy for Cancer Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anti-VEGF Therapy for Cancer Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Anti-VEGF Therapy for Cancer Revenue (2021-2032)
  2. 10.2 China Anti-VEGF Therapy for Cancer Revenue by Type (2021-2032)
  3. 10.2.1 China Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026)
  4. 10.2.2 China Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032)
  5. 10.3 China Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032)
  6. 10.4 China Anti-VEGF Therapy for Cancer Revenue by Application (2021-2032)
  7. 10.4.1 China Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026)
  8. 10.4.2 China Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032)
  9. 10.5 China Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti-VEGF Therapy for Cancer Revenue (2021-2032)
  2. 11.2 Asia Anti-VEGF Therapy for Cancer Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032)
  5. 11.3 Asia Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anti-VEGF Therapy for Cancer Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032)
  9. 11.5 Asia Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anti-VEGF Therapy for Cancer Revenue by Country
  11. 11.6.1 Asia Anti-VEGF Therapy for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anti-VEGF Therapy for Cancer Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anti-VEGF Therapy for Cancer Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti-VEGF Therapy for Cancer Revenue (2021-2032)
  2. 12.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anti-VEGF Therapy for Cancer Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anti-VEGF Therapy for Cancer Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country
  11. 12.6.1 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anti-VEGF Therapy for Cancer Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst